Table 2.
Study treatmenta
| Strategy‐A,N = 98 | Strategy‐B,N = 93 | |
|---|---|---|
| Treatment modalities | ||
| 1 OAM | 2 (2.0) | 2 (2.2) |
| 2 OAMs | 23 (23.5) | 38 (40.9) |
| 3 OAMs | 32 (32.7) | 30 (32.3) |
| 1 OAM + injectable | 15 (15.3) | 1 (1.1) |
| 2 OAMs + injectable | 18 (18.4) | 7 (7.5) |
| 3 OAMs + injectable | 7 (7.1) | 14 (15.1) |
| Injectable only | 1 (1.0) | 1 (1.1) |
| Study drug | ||
| Biguanides: Metformin | 82 (83.7) | 83 (89.2) |
| DPP‐4 Inhibitors | 66 (67.3) | 46 (49.5) |
| Sitagliptin | 50 (51.0) | 34 (36.6) |
| Linagliptin | 16 (16.3) | 12 (12.9) |
| SUs: Glimepiride | 1 (1.0)b | 89 (95.7) |
| TZDs: Pioglitazone | 59 (60.2) | 7 (7.5) |
| α Glucosidase inhibitors: acarbose | 8 (8.2) | 0 |
| GLP‐1 RAs | 40 (40.8) | 0 |
| Liraglutide | 17 (17.3) | 0 |
| Exenatide QW | 22 (22.4) | 0 |
| Exenatide BID | 1 (1.0) | 0 |
| Insulin glargine | 2 (2.0)b | 23 (24.7) |
Abbreviations: BID, twice daily; DPP‐4, dipeptidyl peptidase‐4; GLP‐1 RAs, glucagon‐like peptide‐1 receptor agonists; OAM, oral anti‐hyperglycaemic medication; QW, once weekly; SUs, sulphonylureas; TZDs, thiazolidinediones.
Data are presented as n (%).
a
Maximum line of therapy.
b
These patients (protocol violations) were included in the analysis as the small numbers in each strategy were not anticipated to effect the study results.